Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 12/20 | 0.41 |
| ▸ | RAF1 | P04049 | 8/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3593604 | 0.80 | MAPK14 (0.44) | LMNANPC1RAB9ASMN1; SMN2BRAF | |
| SCHEMBL3016002 | 0.69 | LMNA (0.48) | LMNANPC1RAB9ASMN1; SMN2BRAF | |
| SCHEMBL3591361 | 0.68 | LMNA (0.48) | LMNANPC1RAB9ASMN1; SMN2BRAF | |
| SCHEMBL3594934 | 0.68 | LMNA (0.48) | LMNANPC1RAB9ASMN1; SMN2BRAF | |
| SCHEMBL4038564 | 0.67 | MAPK14 (0.43) | MAPK14 | |
| SCHEMBL3014317 | 0.67 | BRAF (0.54) | LMNANPC1RAB9ASMN1; SMN2BRAF | |
| SCHEMBL3016256 | 0.67 | MAPK14 (0.52) | LMNANPC1RAB9ASMN1; SMN2BRAF | |
| SCHEMBL3020814 | 0.67 | LCK (0.51) | BRAFMAPK14 | |
| SCHEMBL3590926 | 0.66 | LMNA (0.46) | LMNANPC1RAB9ASMN1; SMN2BRAF | |
| SCHEMBL3590882 | 0.66 | MAPK14 (0.42) | LMNANPC1RAB9ASMN1; SMN2BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202876-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-06-19 | — | — | US | disclosed |
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | FYN, ABL2, LCK | LMNA 3788/4885NPC1 3863/4885RAB9A 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.